FR2878747B1 - Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih - Google Patents

Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih

Info

Publication number
FR2878747B1
FR2878747B1 FR0412862A FR0412862A FR2878747B1 FR 2878747 B1 FR2878747 B1 FR 2878747B1 FR 0412862 A FR0412862 A FR 0412862A FR 0412862 A FR0412862 A FR 0412862A FR 2878747 B1 FR2878747 B1 FR 2878747B1
Authority
FR
France
Prior art keywords
treatment
omega
fatty acid
infected patients
hiv infected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0412862A
Other languages
English (en)
Other versions
FR2878747A1 (fr
Inventor
Jean Gardette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0412862A priority Critical patent/FR2878747B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to CA002589797A priority patent/CA2589797A1/fr
Priority to AU2005311266A priority patent/AU2005311266A1/en
Priority to PCT/EP2005/056431 priority patent/WO2006058920A1/fr
Priority to MX2007006561A priority patent/MX2007006561A/es
Priority to EP05816108A priority patent/EP1827414A1/fr
Priority to CNA2005800412354A priority patent/CN101068542A/zh
Priority to RU2007123368/15A priority patent/RU2007123368A/ru
Priority to JP2007543861A priority patent/JP2008521863A/ja
Priority to KR1020077015265A priority patent/KR20070089216A/ko
Priority to US11/792,060 priority patent/US20080113046A1/en
Priority to BRPI0515823-0A priority patent/BRPI0515823A/pt
Publication of FR2878747A1 publication Critical patent/FR2878747A1/fr
Application granted granted Critical
Publication of FR2878747B1 publication Critical patent/FR2878747B1/fr
Priority to IL183349A priority patent/IL183349A0/en
Priority to NO20073318A priority patent/NO20073318L/no
Priority to ZA200705392A priority patent/ZA200705392B/xx
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FR0412862A 2004-12-03 2004-12-03 Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih Expired - Fee Related FR2878747B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0412862A FR2878747B1 (fr) 2004-12-03 2004-12-03 Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
US11/792,060 US20080113046A1 (en) 2004-12-03 2005-12-02 Use of Omega-3 Fatty Acid(s) for Treating Hypercholesterolemia Caused by Anti-Retroviral Treatment of Hiv-Infected Patients
PCT/EP2005/056431 WO2006058920A1 (fr) 2004-12-03 2005-12-02 Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
MX2007006561A MX2007006561A (es) 2004-12-03 2005-12-02 Uso de acido(s) graso s) omega-3 para el tratamiento de la hipercolesterolemia causada por el tratamiento antirretroviral de los pacientes infectados con vih.
EP05816108A EP1827414A1 (fr) 2004-12-03 2005-12-02 Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
CNA2005800412354A CN101068542A (zh) 2004-12-03 2005-12-02 Omega－3脂肪酸在治疗由HIV感染者的抗逆转录病毒治疗引起的高胆固醇血症中的用途
RU2007123368/15A RU2007123368A (ru) 2004-12-03 2005-12-02 Применение омега-3 жирных кислот для лечения гиперхолестеринемии, вызванной противоретровирусным лечением, у вич-инфицированных больных
JP2007543861A JP2008521863A (ja) 2004-12-03 2005-12-02 Ｈｉｖ感染患者における抗レトロウイルス治療がひき起こす高コレステロール血症の治療のためのオメガ−３脂肪酸の利用
CA002589797A CA2589797A1 (fr) 2004-12-03 2005-12-02 Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
AU2005311266A AU2005311266A1 (en) 2004-12-03 2005-12-02 Use of omega-3 fatty acid(s) for treating hypercholesterolemia caused by anti-retroviral treatment of HIV-infected patients
BRPI0515823-0A BRPI0515823A (pt) 2004-12-03 2005-12-02 utilização de ácido(s) graxo(s) Èmega-3 para o tratamento da hipercolesterolemia causada por um tratamento anti-retroviral nos pacientes infectados pelo hiv
KR1020077015265A KR20070089216A (ko) 2004-12-03 2005-12-02 Ｈｉｖ―감염자의 바이러스성 치료로 인해 생기는고콜레스테롤혈증을 치료하기 위한 오메가3지방산의 사용방법
IL183349A IL183349A0 (en) 2004-12-03 2007-05-21 Use of omega-3 fatty acid(s) for treating hypercholesterolemia caused by anti-retroviral treatment of hiv-infected patients
NO20073318A NO20073318L (no) 2004-12-03 2007-06-27 Anvendelse av omega-3 fettsyre(r) til a behandle hyperkolesterolemi forarsaket av antiretroviral behandling av HfV-infiserte pasienter
ZA200705392A ZA200705392B (en) 2004-12-03 2007-07-03 Use of omega-3 fatty acid(s) for treating hypercholesterolemia caused by anti-retroviral treatment of HIV-infected patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412862A FR2878747B1 (fr) 2004-12-03 2004-12-03 Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih

Publications (2)

Publication Number Publication Date
FR2878747A1 FR2878747A1 (fr) 2006-06-09
FR2878747B1 true FR2878747B1 (fr) 2007-03-30

Family

ID=34952290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0412862A Expired - Fee Related FR2878747B1 (fr) 2004-12-03 2004-12-03 Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih

Country Status (15)

Country Link
US (1) US20080113046A1 (fr)
EP (1) EP1827414A1 (fr)
JP (1) JP2008521863A (fr)
KR (1) KR20070089216A (fr)
CN (1) CN101068542A (fr)
AU (1) AU2005311266A1 (fr)
BR (1) BRPI0515823A (fr)
CA (1) CA2589797A1 (fr)
FR (1) FR2878747B1 (fr)
IL (1) IL183349A0 (fr)
MX (1) MX2007006561A (fr)
NO (1) NO20073318L (fr)
RU (1) RU2007123368A (fr)
WO (1) WO2006058920A1 (fr)
ZA (1) ZA200705392B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP4137128A1 (fr) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Composition pharmaceutique contenant de l'acide eicosapentaénoïque et leurs procédés d'utilisation
ES2768091T3 (es) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
MX350088B (es) 2009-04-29 2017-08-25 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
AU2016203375B2 (en) * 2009-04-29 2017-11-30 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2014200070B2 (en) * 2009-04-29 2016-06-16 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2009354456B2 (en) 2009-10-30 2014-05-08 Tharos Ltd Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US8691297B2 (en) * 2010-09-01 2014-04-08 Nippon Suisan Kaisha, Ltd. Alcoholic injury mitigating agent
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
WO2013192109A1 (fr) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation
CA3067012C (fr) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Procedes de reduction du risque d'un evenement cardiovasculaire chez un sujet soumis a un traitement par une statine
EP2911657A4 (fr) * 2012-10-23 2016-08-03 Univ Deakin Procédé pour la réduction de triglycérides
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114711321B (zh) * 2022-03-19 2024-03-15 浙江新研坤科技有限公司 添加有植物型欧米伽3的南极磷虾油凝胶糖果及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141923A (en) * 1990-12-31 1992-08-25 Immunology, Inc., A California Corporation Methods for the treatment of retroviral infections
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
US6511983B1 (en) * 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
DE19956400B4 (de) * 1999-11-24 2005-09-08 Sagredos, Angelos, Prof. Dr. Therapeutisch wirksame Zusammensetzung, ein Verfahren zu ihrer Herstellung und ihre Verwendung
ES2246769T3 (es) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
BRPI0515823A (pt) 2008-08-05
ZA200705392B (en) 2008-11-26
MX2007006561A (es) 2007-06-15
JP2008521863A (ja) 2008-06-26
EP1827414A1 (fr) 2007-09-05
CN101068542A (zh) 2007-11-07
KR20070089216A (ko) 2007-08-30
US20080113046A1 (en) 2008-05-15
RU2007123368A (ru) 2009-01-10
IL183349A0 (en) 2008-04-13
NO20073318L (no) 2007-06-27
AU2005311266A1 (en) 2006-06-08
FR2878747A1 (fr) 2006-06-09
CA2589797A1 (fr) 2006-06-08
WO2006058920A1 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
FR24C1024I2 (fr) Combinaisons du dolutégravir et de la lamivudine destinées au traitement de l'infection au vih
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
IL183349A0 (en) Use of omega-3 fatty acid(s) for treating hypercholesterolemia caused by anti-retroviral treatment of hiv-infected patients
FR2918994B1 (fr) Formulations de diesters d'acide carboxylique et leur utilisation pour le traitement de materiaux.
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
EP2255804A4 (fr) Composition pharmaceutique et son utilisation dans la préparation d'un médicament pour le traitement de maladies vasculaires cérébrales
EP1773355A4 (fr) Phosphoramidates d'aryle nucleosidiques pour le traitement d'infection virale arn dependante de l'arn
EP2120566A4 (fr) Composés et compositions pharmaceutiques destinés au traitement d'infections virales
EP1725535A4 (fr) Inhibiteurs de l'integrase du vih
EP1536804A4 (fr) Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
TNSN91029A1 (fr) Les analogues du nucleoside de 1,3-oxathiolane
EP1720856A4 (fr) Inhibiteurs de l'integrase du vih
AR038385A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
EP2056848A4 (fr) Utilisation d'extraits pour le traitement de troubles viraux
MA28519B1 (fr) Inhibiteurs de l'integrase du vih
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
MY186986A (en) Compositions and methods of use of phorbol esters
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
EP1725102A4 (fr) Inhibiteurs de l'integrase du vih
EP3920903A4 (fr) Utilisation d'un agoniste ppar-delta dans le traitement de troubles d'oxydation des acides gras (faod)
EP2187897A4 (fr) Composition pour la prévention d'infection virale comportant de l'acide gamma polyglutamique
EP2579867A4 (fr) Régime à base de triheptanoïne pour le traitement de la maladie des corps de polyglucosane de l'adulte (apbd)
EP1930002A4 (fr) Utilisation d'ester d'acide hydroxybenzoïque et d'analogues pour la fabrication d'un médicament pour la prévention et le traitement d'infection virale
EP3758716A4 (fr) Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100831